Exercise News and Research

Latest Exercise News and Research

Brisk walking avoids obesity

Men and women who walk or ride a bike to work appear more fit, and men are less likely to be overweight or obese and have healthier triglyceride levels, blood pressure and insulin levels, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

1 Sep 2009

Research reveals that practicing Tetris increases brain efficiency

Researchers at the Mind Research Network today announced the findings of a scientific study that used brain imaging and Tetris to investigate whether practice makes the brain efficient because it increases gray matter. Over a three-month period, adolescent girls practiced Tetris, a computer game requiring a combination of cognitive skills. The girls who practiced showed greater brain efficiency, consistent with earlier studies. Compared to controls, the girls that practiced also had a thicker cortex, but not in the same brain areas where efficiency occurred.

1 Sep 2009

New study reveals that moderate aerobic exercise improves insulin sensitivity in obese adolescents

A moderate aerobic exercise program, without weight loss, can improve insulin sensitivity in both lean and obese sedentary adolescents, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Insulin is a hormone produced in the pancreas that permits glucose to enter cells to be used for energy or stored for future use by the body.

1 Sep 2009

Brain research reveals that juggling practice increased gray matter in the motor areas of the brain

1 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Daxor's signed trial agreement with Pacific Cardiology to provide the BVA-100 instrument

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Pacific Cardiology, LLC of Honolulu, Hawaii. This will provide Pacific Cardiology with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume.

1 Sep 2009

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Many Rite Aid pharmacists have already been giving regular seasonal flu shots following the Centers for Disease Control and Prevention (CDC) advice that anyone who wishes to reduce the risk of getting the regular seasonal flu get a flu shot as soon as they are available.

31 Aug 2009

XerGame products to be showcased at the US Open Tennis Championships

XerTech Inc., a leading manufacturer, seller, and distributer of cutting-edge, interactive fitness systems, today announced that it will showcase its XerGame products at the US Open Tennis Championships, starting today, August 31, and running through the end of the event on September 13, 2009.

31 Aug 2009

Health Net urges Americans to have their blood cholesterol measured

Tomorrow, September 1, marks the start of National Cholesterol Education Month. In support of this educational effort, Health Net, Inc., (NYSE: HNT) is encouraging those who haven't yet done so, to have their blood cholesterol measured and, if it's high, to embark on a cholesterol-lowering program.

31 Aug 2009

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.

31 Aug 2009

Fitness and weight loss are the main reasons behind European runners

To honour its 60th anniversary this year, ASICS took its expertise in running to another level by conducting an unprecedented research into the mind of the runner. Executed by the research institute Synovate, ASICS' 'Reasons to Run' research asked more than 3,500 runners in seven European countries* to reveal the 'why?' behind their actions, making it the biggest study of its kind ever.

31 Aug 2009

People who drink alcohol are likely to exercise more than teetotalers

Drinkers aren't just bending their elbows: according to a new study, the more alcohol people drink, the more likely they might be to exercise.

31 Aug 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Weight loss competition to be held to bring a new focus on healthy living

WDIV-TV, Blue Cross Blue Shield of Michigan and The Parade Company will launch The Biggest Loser: Detroit Edition contest on Monday, August 31. Six contestants from Metro Detroit have been selected from approximately 200 applicants to compete in this 12-week weight loss challenge to be featured on ClickonDetroit.com.

29 Aug 2009

Ranaz Corporation to raise funds through private placement

Ranaz Corporation ("Ranaz") (TSXV: RNZ), a company specialized in the manufacturing and marketing of protein and dietary supplements, announces that it intends to raise $675,000 through a non-brokered private placement of units.

29 Aug 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

Researchers develop an index scale to help physicians predict a patient's risk of dying from COPD

Researchers have developed an index scale to help physicians predict a patient's risk of dying from chronic obstructive pulmonary disease (COPD). The ADO index can help physicians assess the severity of a patient's illness to determine the appropriate level of treatment. COPD, which comprises emphysema and chronic bronchitis, is a major public health problem and it is the fourth leading cause of death in the U.S. The study of the ADO index is published in the August 29 edition of the Lancet.

29 Aug 2009

Metiscan closes equity funding of $7.3M

Metiscan, Inc. (PINKSHEETS: MTIZ), a holding company focused on growing its organization by making key acquisitions and developing companies and emerging technologies, announced today that it has closed an equity funding of $7.3M, which has been deposited in a restricted cash account owned by Metiscan. Funds shall be distributed subject to a registration statement filed with the SEC becoming effective and other conditions outlined in an account management agreement. The investors also have the option to exercise warrants up to $10M.

28 Aug 2009

CNS Response raises funds through private placement for general corporate purposes

CNS Response, Inc. (OTCBB: CNSO) (the "Company") today announced that it has completed a closing of its private placement, resulting in gross proceeds to the Company of approximately $2,000,000.

28 Aug 2009